Support PenkeNovo Nordisk A/S - Trending symbols
Latest News of Novo Nordisk A/S
| Date | Title | Read |
|---|---|---|
| 2025-03-29 19:33 | Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025 | Read |
| 2025-03-29 15:33 | Ozempic® (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD) at ACC 2025 | Read |
| 2025-03-28 22:45 | Novo Nordisk (NVO) Stock Moves -1.23%: What You Should Know | Read |
| 2025-03-28 22:25 | Is Novo Nordisk (NVO) the Best ADR Stock to Buy According to Hedge Funds? | Read |
| 2025-03-28 17:07 | Novo Nordisk Q1 Earnings Likely to Miss Estimates on Slower Ozempic, Wegovy Sales, BofA Says | Read |
| 2025-03-28 15:09 | Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1 | Read |
| 2025-03-28 14:54 | BofA cuts Novo Nordisk shares target on expected Q1 earnings miss | Read |
| 2025-03-28 14:00 | Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know | Read |
| 2025-03-27 22:04 | Wegovy sales took a hit this year. Novo's CEO blames off-brand competition | Read |
| 2025-03-27 18:29 | Novo shares on track for biggest monthly fall since 2002, investor worries grow | Read |
Notifications
| Type | Notification | Date |
|---|---|---|
| RSI Oversold | Oversold RSI (Relative Strength Index) | 2025-03-27 |
Trends
| 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Reconciled Depreciation | 2,992,000 | -78,000 | 2,914,000 | 5,931,000 | 8,845,000 | -6,695,000 | 2,150,000 | -7,514,000 | -5,364,000 | |
| Interest Income | 3,200,000 | -2,348,000 | 852,000 | -205,000 | 647,000 | 2,671,000 | 3,318,000 | -6,138,000 | -2,820,000 | |
| Interest Expense | 8,037,000 | -6,915,000 | 1,122,000 | -841,000 | 281,000 | 1,887,000 | 2,168,000 | -4,269,000 | -2,101,000 | |
| Total Other Income Expense Net | -1,596,000 | -556,000 | -2,152,000 | 1,381,000 | -771,000 | 501,000 | -270,000 | 636,000 | 366,000 | |
| Net Interest Income | -1,137,000 | -91,000 | -1,228,000 | -368,000 | -1,596,000 | -556,000 | -2,152,000 | 6,808,000 | 4,656,000 | |
| Other Stockholders Equity | -3,000 | -1,000 | -4,000 | -2,000 | -6,000 | -1,000 | -7,000 | 840,000 | 833,000 | |
| Other Operating Expenses | 18,262,000 | 2,111,000 | 20,373,000 | 4,326,000 | 24,699,000 | -1,815,000 | 22,884,000 | -23,033,000 | -149,000 |
Comments
How you think about this?